BEARINGPOINT
22.4.2021 09:57:05 CEST | Business Wire | Press release
Climate change is increasing pressure on companies to take immediate actions to measure, manage, and report greenhouse gas emissions from their operations and value chains. In its recent client story, management and technology consultancy BearingPoint shows how it supported Wipak, a global supplier of packaging solutions and services, in taking a significant step on its journey to reducing its carbon footprint to zero by 2025 by accurately calculating its carbon emissions and gaining transparency across the entire product life-cycle process.
BearingPoint leveraged its Emissions Calculator solution and used a cradle-to-gate approach during a series of workshops to identify Wipak’s key impact areas and aligned them with data requirements. The team then analyzed the processes and data availability for material acquisition, freight transportation, manufacturing sites, warehouses, and support processes related to sales offices and business travel. All data was centralized in a collection plan to feed BearingPoint’s standard data templates, followed by integrating it into the software solution. This resulted in a corporate carbon footprint (CCF), including scopes 1, 2, and 3 according to the Greenhouse Gas Protocol (GHG). Wipak also added the product carbon footprint (PCF) module to support sharing carbon data with clients down to the product level. BearingPoint supported the client to select the allocation methods and relevant secondary data sources, determining every product’s climate impact, from raw material sourcing to their recycling or disposal.
Mika Niemelä, Partner at BearingPoint: “Consumer perception and corporate customers’ demands regarding sustainable packaging are driving Wipak to seek flexible and resource-efficient solutions. At the same time, Wipak needed to ensure accurate carbon footprint calculations to comply with future sustainability regulations and laws, and it now can with our Emission Calculator solution. Today, with our solution, the company is well on its way to achieving a zero-carbon footprint by 2025.”
Wipak can now accurately calculate its carbon emissions that allow for tracking its achievements toward decarbonization on a daily level. Already from the validation phase, the application assesses and summarizes more than 1,400 purchased goods, 3,500 semi-finished products, and 4,700 finished products daily, based on a big data approach.
BearingPoint’s Emissions Calculator also enables the company to make data-driven business decisions toward reducing its carbon footprint to zero by 2025, based on all information centralized in one place and analytic tool-derived insights. The solution offers a comprehensive picture of which region, business line, or product is causing the highest emissions. Wipak also benefits from continuous updates from leading standards such as GHG protocol, ISO 14064, ISO 14067, or GLEC. This ensures that the company is better prepared to meet internal audit requirements, as well as to comply with future sustainability regulations and laws.
Dorit Nelke-Bruhn, Manager Sustainability Processes and Patents, Wipak Group: “To support us on our journey to become the most sustainable flexible packaging company, we were searching for a professional and trusted carbon accounting software to calculate corporate and product carbon footprints. BearingPoint’s Emissions Calculator fulfills our needs. It supports us to assess GHG emissions of raw materials, our production facilities, freight transportation, and support processes such as business travel and sales offices and to identify emission reduction potentials.”
About Wipak Group
Wipak is part of the family owned Wihuri Group, a diverse Finnish conglomerate that can trace its origins back over 100 years. Today the Wihuri group employs 5,000 people with operations in 30 countries.
Wihuri´s Packaging business is one of the world's leading producers of packaging materials and solutions for the Food and Medical supply industries in Europe and North America. Wihuri’s Packaging Division consists of two international brands: WIPAK in Europe and Asia and WINPAK in North America. More information about Winpak can be found below.
Wipak develops and manufactures highly innovative premium-quality flexible packaging solutions for Food products and Medical Instruments and Devices.
www.wipak.com
https://www.linkedin.com/company/wipak/
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units. The first unit covers the advisory business with a clear focus on five key areas to drive growth across all regions. The second unit provides IP-driven managed services beyond SaaS and offers business-critical services to its clients, supporting their business success. The third unit provides the software for successful digital transformation. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005056/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 19:00:00 CEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom